Non-alcoholic Steatohepatitis (NASH) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeu

Non-alcoholic Steatohepatitis (NASH) Pipeline constitutes 80+ key companies continuously working towards developing 80+ Non-alcoholic Steatohepatitis (NASH) treatment therapies, analyzes DelveInsight.

Non-alcoholic Steatohepatitis (NASH) Overview:

Nonalcoholic steatohepatitis (NASH) is a liver condition characterized by inflammation and damage caused by fat buildup in the liver. It falls under the broader category of nonalcoholic fatty liver disease (NAFLD), which is divided into two types: isolated fatty liver, where only fat accumulates, and NASH, where fat buildup is accompanied by inflammation and liver cell damage. Over time, NASH can progress to liver fibrosis, cirrhosis, and liver cancer, with 30-40% of patients developing fibrosis. NASH is not a condition exclusive to NAFLD and can also be linked to other liver diseases, such as chronic hepatitis C.

NASH is typically categorized into primary NASH (linked to obesity and diabetes without excessive alcohol use) and secondary NASH (caused by toxins or drugs). Key risk factors include obesity, metabolic syndrome, insulin resistance, and type 2 diabetes, which are strongly associated with the disease. Other conditions such as PCOD, Wilson disease, and lipodystrophies are also linked to NASH.

The development of NASH follows the "two-hit" hypothesis: the first hit involves fat buildup in the liver (steatosis), and the second hit involves oxidative stress and liver cell injury. This leads to mitochondrial dysfunction, inflammation, and eventual liver damage, progressing to fibrosis and cirrhosis. Diagnosis is often incidental, detected through abnormal liver tests or imaging. While liver biopsy remains the gold standard for diagnosing NASH, it has limitations, and non-invasive tests like FibroScan and APRI are often used to assess liver damage.

Treatment for NASH primarily focuses on lifestyle changes, such as weight loss (5%-10%), exercise, and dietary adjustments, including reducing high fructose corn syrup and increasing omega-3 fatty acids. Medications like antioxidants (vitamin E) and thiazolidinediones may also help, but caution is needed with the latter. Bariatric surgery can be an option for severely obese patients, and liver transplantation is considered for those with advanced cirrhosis, though there is a risk of NASH recurrence.

Request for a detailed insights report on Non-alcoholic Steatohepatitis (NASH) pipeline insights @ https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-alcoholic Steatohepatitis (NASH) Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-alcoholic Steatohepatitis (NASH) Therapeutics Market.

Key Takeaways from the Non-alcoholic Steatohepatitis (NASH) Pipeline Report

DelveInsight's Non-alcoholic Steatohepatitis (NASH) pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Non-alcoholic Steatohepatitis (NASH) treatment.
In November 2024, Novo Nordisk announced positive results for semaglutide in treating Nonalcoholic Steatohepatitis (NASH). The Phase 3 Essence trial showed that a once-weekly 2.4 mg dose of semaglutide significantly improved liver fibrosis and resolved steatohepatitis in NASH patients with stage 2 or 3 fibrosis, without worsening liver fibrosis, successfully meeting the primary endpoints.
In October 2024, Sagimet Biosciences (SGMT) revealed the successful conclusion of end-of-Phase 2 discussions with the FDA, allowing denifanstat to move forward into Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis.
In July 2024, Inventiva provided updates on its Phase III NATiV3 clinical program, assessing lanifibranor for treating metabolic dysfunction-associated steatohepatitis/non-alcoholic steatohepatitis (MASH/NASH). Recruitment for the trial is currently underway at 347 sites across 19 countries.
Key Non-alcoholic Steatohepatitis (NASH) companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others are evaluating new drugs for Non-alcoholic Steatohepatitis (NASH) to improve the treatment landscape.
Promising Non-alcoholic Steatohepatitis (NASH) pipeline therapies in various stages of development include Lanifibranor, MSDC-0602K, TERN-501, HTD 1801, and others.

Non-alcoholic Steatohepatitis (NASH) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-alcoholic Steatohepatitis (NASH) Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-alcoholic Steatohepatitis (NASH) treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-alcoholic Steatohepatitis (NASH) market.

Download our free sample page report on Non-alcoholic Steatohepatitis (NASH) pipeline insights @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-alcoholic Steatohepatitis (NASH) Emerging Drugs

Lanifibranor: Inventiva Pharma
MSDC-0602K: Cirius Therapeutics
TERN-501: Terns Pharmaceuticals
HTD 1801: HighTide Biopharma

Non-alcoholic Steatohepatitis (NASH) Companies

There are over 80 major companies working on therapies for Nonalcoholic Steatohepatitis. Among them, Cirius Therapeutics and Inventiva Pharma have drug candidates in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 22+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Non-alcoholic Steatohepatitis (NASH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-alcoholic Steatohepatitis (NASH) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-alcoholic Steatohepatitis (NASH) Therapies and Key Companies: Non-alcoholic Steatohepatitis (NASH) Clinical Trials and advancements @ https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-alcoholic Steatohepatitis (NASH) Pipeline Therapeutic Assessment
• Non-alcoholic Steatohepatitis (NASH) Assessment by Product Type
• Non-alcoholic Steatohepatitis (NASH) By Stage
• Non-alcoholic Steatohepatitis (NASH) Assessment by Route of Administration
• Non-alcoholic Steatohepatitis (NASH) Assessment by Molecule Type

Download Non-alcoholic Steatohepatitis (NASH) Sample report to know in detail about the Non-alcoholic Steatohepatitis (NASH) treatment market @ Non-alcoholic Steatohepatitis (NASH) Therapeutic Assessment @ https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-alcoholic Steatohepatitis (NASH) Current Treatment Patterns
4. Non-alcoholic Steatohepatitis (NASH) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-alcoholic Steatohepatitis (NASH) Late-Stage Products (Phase-III)
7. Non-alcoholic Steatohepatitis (NASH) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-alcoholic Steatohepatitis (NASH) Discontinued Products
13. Non-alcoholic Steatohepatitis (NASH) Product Profiles
14. Non-alcoholic Steatohepatitis (NASH) Key Companies
15. Non-alcoholic Steatohepatitis (NASH) Key Products
16. Dormant and Discontinued Products
17. Non-alcoholic Steatohepatitis (NASH) Unmet Needs
18. Non-alcoholic Steatohepatitis (NASH) Future Perspectives
19. Non-alcoholic Steatohepatitis (NASH) Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-alcoholic Steatohepatitis (NASH) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.